A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Glabellar Lines
Interventions
DRUG

AGN-151586

Intramuscular injection

DRUG

OnabotulinumtoxinA

Intramuscular injection

DRUG

Placebo

Intramuscular injection

Trial Locations (8)

22209

SkinDC /ID# 270932, Arlington

28403

Wilmington Dermatology Center /ID# 270828, Wilmington

78660

Austin Institute for Clinical Research - Pflugerville /ID# 270834, Pflugerville

85260

Investigate MD /ID# 270771, Scottsdale

90277

Marcus Facial Plastic Surgery /ID# 270770, Redondo Beach

92663

Eye Research Foundation /ID# 270827, Newport Beach

33146-1837

Skin Research Institute LLC /ID# 270831, Coral Gables

02467

Skincare Physicians /ID# 271018, Chestnut Hill

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY